53 active shortage notices across 10 countries · 4 anticipated.
Last updated 17 Sept 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Australia | critical | 6 | 26 Sept 2025 | 29 Jan 2027 | TGA |
| United States | high | 1 | 21 Jan 2025 | — |
| Colombia | high | 1 | 29 May 2024 | — | INVIMA |
| Netherlands | medium | 25 | 9 Mar 2026 | — | CBG-MEB |
| Canada | medium | 11 | 17 Sept 2018 | 31 Jan 2027 | HC |
| Italy | medium | 3 | 12 Mar 2026 | — | AIFA |
| Peru | medium | 3 | 28 Jan 2020 | 25 May 2025 | DIGEMID |
| Spain | medium | 1 | 9 Sept 2026 | 22 Sept 2026 | AEMPS |
| Belgium | medium | 1 | 6 Jul 2026 | 5 Aug 2026 | FAMHP |
| Ireland | medium | 1 | 13 Feb 2026 | 24 Feb 2026 | HPRA |
Clinically related options from Mederti's curated alternatives data. Always confirm suitability with a pharmacist or prescriber before substituting.
Yes. As of the latest regulator updates, Irbesartan has 53 active shortage notices across 10 countries (Australia, United States, Colombia, Netherlands, Canada, Italy and more). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Irbesartan shortages to supply-chain disruption, manufacturing problems, product discontinuation. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 30 Jun 2020 to 31 Jan 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Mederti lists 5 clinically related alternatives for Irbesartan (see the alternatives section above). Alternatives require clinical judgement — always confirm suitability with a pharmacist or prescriber and your national guidance before substituting.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Candesartan Cilexetil · Olmesartan Medoxomil · Valsartan · Telmisartan · Candesartan Viatris · Candesartan Sun
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.